EXELIXIS INC. news, videos and press releases
For more news please use our advanced search feature.
EXELIXIS INC. - More news...
EXELIXIS INC. - More news...
- Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
- Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
- Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
- Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
- Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
- Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
- Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
- Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
- Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
- Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
- Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
- Exelixis Advances Board Refreshment Plan
- Exelixis Reiterates Commitment to Shareholder Value Creation
- Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
- Exelixis Announces $550 Million Share Repurchase Program
- Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
- Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
- Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
- Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
- Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
- Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
- Exelixis Announces Update on Patent Litigation with MSN Laboratories
- Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
- Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
- Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
